Kinase-driven pathways of EGFR in lung carcinomas: Perspectives on targeting therapy

Frontiers in Bioscience

Volumn 16, Issue 5, 2011, Pages 1714-1732

  Dobashi, Yoh ^a   Koyama, Shinichiro ^a   Kanai, Yoshihiko ^a   Tetsuka, Kenji ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Akt; ; EGFR; Lung Carcinoma; Molecular targeted therapy; mTOR; p70S6 kinase; Review

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MTOR PROTEIN, HUMAN; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE; STAT3 PROTEIN; TARGET OF RAPAMYCIN KINASE;

ADENOCARCINOMA; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TOR SERINE-THREONINE KINASES;

EID: 79955065722     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3815     Document Type: Article

References (135)

1. K. Takeda, T. Hida, T. Sato, M. Ando, T. Seto, M. Satouchi, Y. Ichinose, N. Katakami, N. Yamamoto, S. Kudoh, J. Sasaki, K. Matsui, K. Takayama, T. Kashii, Y. Iwamoto, T. Sawa, I. Okamoto, T. Kurata, K. Nakagawa and M. Fukuoka: Randomized phase III trial of platinumdoublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203). J Clin Oncol 28(5), 753-760 (2010)
2. S. Dacic, Y. Shuai, S. Yousem, P. Ohori and M. Nikiforova: Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas. Mod Pathol 23(2), 159-168 (2010)
3. S. V. Sharma, D. W. Bell, J. Settleman and D. A. Haber: Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7(3), 169-181 (2007)
4. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu and M. J. Thun: Cancer statistics, 2009. CA Cancer J Clin 59(4), 225-49 (2009)
5. H. Kunitoh, H. Kato, M. Tsuboi, H. Asamura, H. Tada, K. Nagai, T. Mitsudomi, T. Koike, K. Nakagawa, Y. Ichinose, M. Okada, T. Shibata and N. Saijo: A randomized phase II trial of preoperative chemotherapy of cisplatindocetaxel or docetaxel alone for clinical stage IB/II nonsmall- cell lung cancer results of a Japan Clinical Oncology Group trial (JCOG 0204). Br J Cancer 99(6), 852-857 (2008)
6. C. T. Travis WD, Corrin B, Shimosato Y, Brambilla E. In collaboration with L.H. Sobin and Pathologists from 14 Countries.: The World Health Organization. Histological typing of lung and pleural tumours. (3rd edn.). Springer, New York (1999.)
7. W. C. Dempke, T. Suto and M. Reck: Targeted therapies for non-small cell lung cancer. Lung Cancer 67(3), 257-274 (2010 )
8. D. N. Hayes, S. Monti, G. Parmigiani, C. B. Gilks, K. Naoki, A. Bhattacharjee, M. A. Socinski, C. Perou and M. Meyerson: Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. J Clin Oncol 24(31), 5079-5090 (2006) (Pubitemid 46631412)
9. G. Selvaggi and G. V. Scagliotti: Histologic subtype in NSCLC: does it matter? Oncology (Williston Park) 23(13), 1133-1140 (2009)
10. D. G. Pfister, D. H. Johnson, C. G. Azzoli, W. Sause, T. J. Smith, S. Baker, Jr., J. Olak, D. Stover, J. R. Strawn, A. T. Turrisi and M. R. Somerfield: American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22(2), 330-353 (2004) (Pubitemid 41095099)
11. Y. Ohe, Y. Ohashi, K. Kubota, T. Tamura, K. Nakagawa, S. Negoro, Y. Nishiwaki, N. Saijo, Y. Ariyoshi and M. Fukuoka: Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 18(2), 317-323 (2007) (Pubitemid 46323100)
12. N. E. Hynes and H. A. Lane: ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5(5), 341-354 (2005) (Pubitemid 40637826)
13. J. Baselga: Targeting tyrosine kinases in cancer: the second wave. Science 312(5777), 1175-1178 (2006) (Pubitemid 43801135)
14. U. McDermott and J. Settleman: Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology. J Clin Oncol 27(33), 5650-5659 (2009)
15. W. Pao and V. A. Miller: Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 23(11), 2556-2568 (2005)
16. T. Mitsudomi: Advances in target therapy for lung cancer. Jpn J Clin Oncol 40(2), 101-106 (2010)
17. G. V. Scagliotti, P. Parikh, J. von Pawel, B. Biesma, J. Vansteenkiste, C. Manegold, P. Serwatowski, U. Gatzemeier, R. Digumarti, M. Zukin, J. S. Lee, A. Mellemgaard, K. Park, S. Patil, J. Rolski, T. Goksel, F. de Marinis, L. Simms, K. P. Sugarman and D. Gandara: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26(21), 3543-3551 (2008)
18. J. C. Soria, E. Smit, D. Khayat, B. Besse, X. Yang, C. P. Hsu, D. Reese, J. Wiezorek and F. Blackhall: Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous nonsmall- cell lung cancer. J Clin Oncol 28(9), 1527-1533 (2010)
19. J. Schlessinger: Common and distinct elements in cellular signaling via EGF and FGF receptors. Science 306(5701), 1506-1507 (2004) (Pubitemid 39564935)
20. S. Suzuki, S. Igarashi, M. Hanawa, H. Matsubara, A. Ooi and Y. Dobashi: Diversity of epidermal growth factor receptor-mediated activation of downstream molecules in human lung carcinomas. Mod Pathol 19(7), 986-998 (2006)
21. R. I. Nicholson, J. M. Gee and M. E. Harper: EGFR and cancer prognosis. Eur J Cancer 37 Suppl 4, S9-15 (2001) (Pubitemid 32938124)
22. H. Sugimura, H. Mori, K. Nagura, S. Kiyose, T. Hong, M. Isozaki, H. Igarashi, K. Shinmura, A. Hasegawa, Y. Kitayama and F. Tanioka: Fluorescence in situ hybridization analysis with a tissue microarray: 'FISH and chips' analysis of pathology archives. Pathol Int 60(8), 543-550 (2010)
23. V. Rusch, D. Klimstra, E. Venkatraman, P. W. Pisters, J. Langenfeld and E. Dmitrovsky: Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 3(4), 515-522 (1997) (Pubitemid 27211827)
24. D. S. Salomon, R. Brandt, F. Ciardiello and N. Normanno: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19(3), 183-232 (1995)
25. C. Gridelli, A. Rossi and P. Maione: Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents. Oncogene 22(42), 6629-6638 (2003) (Pubitemid 37372343)
26. S. Suzuki, Y. Dobashi, H. Sakurai, K. Nishikawa, M. Hanawa and A. Ooi: Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas. An immunohistochemical and fluorescence in situ hybridization study. Cancer 103(6), 1265-1273 (2005) (Pubitemid 40328099)
27. W. A. Franklin, R. Veve, F. R. Hirsch, B. A. Helfrich and P. A. Bunn, Jr.: Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol 29(1 Suppl 4), 3-14 (2002) (Pubitemid 34226514)
28. F. R. Hirsch, M. Varella-Garcia, P. A. Bunn, Jr., M. V. Di Maria, R. Veve, R. M. Bremmes, A. E. Baron, C. Zeng and W. A. Franklin: Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21(20), 3798-3807 (2003) (Pubitemid 46606235)
29. Y. K. Jeon, S. W. Sung, J. H. Chung, W. S. Park, J. W. Seo, C. W. Kim and D. H. Chung: Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer. Lung Cancer 54(3), 387-398 (2006) (Pubitemid 44754719)
30. F. Cappuzzo, F. R. Hirsch, E. Rossi, S. Bartolini, G. L. Ceresoli, L. Bemis, J. Haney, S. Witta, K. Danenberg, I. Domenichini, V. Ludovini, E. Magrini, V. Gregorc, C. Doglioni, A. Sidoni, M. Tonato, W. A. Franklin, L. Crino, P. A. Bunn, Jr. and M. Varella-Garcia: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97(9), 643-655 (2005) (Pubitemid 40812628)
31. F. R. Hirsch, M. Varella-Garcia, P. A. Bunn, Jr., W. A. Franklin, R. Dziadziuszko, N. Thatcher, A. Chang, P. Parikh, J. R. Pereira, T. Ciuleanu, J. von Pawel, C. Watkins, A. Flannery, G. Ellison, E. Donald, L. Knight, D. Parums, N. Botwood and B. Holloway: Molecular predictors of outcome with gefitinib in a phase III placebocontrolled study in advanced non-small-cell lung cancer. J Clin Oncol 24(31), 5034-5042 (2006) (Pubitemid 46631407)
32. H. Endoh, Y. Ishibashi, E. Yamaki, T. Yoshida, T. Yajima, H. Kimura, T. Kosaka, R. Onozato, S. Tanaka, T. Mitsudomi and H. Kuwano: Immunohistochemical analysis of phosphorylated epidermal growth factor receptor might provide a surrogate marker of EGFR mutation. Lung Cancer 63(2), 241-246 (2009)
33. Y. Dobashi, N. Takei, S. Suzuki, H. Yoneyama, M. Hanawa and A. Ooi: Aberration of epidermal growth factor receptor expression in bone and soft-tissue tumors: protein overexpression, gene amplification and activation of downstream molecules. Mod Pathol 17(12), 1497-1505 (2004) (Pubitemid 39627076)
34. F. R. Hirsch, M. Varella-Garcia, J. McCoy, H. West, A. C. Xavier, P. Gumerlock, P. A. Bunn, Jr., W. A. Franklin, J. Crowley and D. R. Gandara: Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol 23(28), 6838-6845 (2005)
35. Y. Dobashi, S. Suzuki, M. Kimura, H. Matsubara, H. Tsubochi, I. Imoto and A. Ooi Paradigm of kinase-driven pathway downstream of EGFR/Akt in human lung carcinomas. Human Pathol (In press.)
36. M. L. Janmaat, F. A. Kruyt, J. A. Rodriguez and G. Giaccone: Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 9(6), 2316-2326 (2003) (Pubitemid 36687658)
37. H. Ji, X. Zhao, Y. Yuza, T. Shimamura, D. Li, A. Protopopov, B. L. Jung, K. McNamara, H. Xia, K. A. Glatt, R. K. Thomas, H. Sasaki, J. W. Horner, M. Eck, A. Mitchell, Y. Sun, R. Al-Hashem, R. T. Bronson, S. K. Rabindran, C. M. Discafani, E. Maher, G. I. Shapiro, M. Meyerson and K. K. Wong: Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci U S A 103(20), 7817-7822 (2006)
38. P. A. Bunn, Jr., R. Dziadziuszko, M. Varella-Garcia, W. A. Franklin, S. E. Witta, K. Kelly and F. R. Hirsch: Biological markers for non-small cell lung cancer patient selection for epidermal growth factor receptor tyrosine kinase inhibitor therapy. Clin Cancer Res 12(12), 3652-3656 (2006) (Pubitemid 44000246)
39. M. Hanawa, S. Suzuki, Y. Dobashi, T. Yamane, K. Kono, N. Enomoto and A. Ooi: EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer 118(5), 1173-1180 (2006) (Pubitemid 43185604)
40. D. D. Von Hoff, J. R. McGill, B. J. Forseth, K. K. Davidson, T. P. Bradley, D. R. Van Devanter and G. M. Wahl: Elimination of extrachromosomally amplified MYC genes from human tumor cells reduces their tumorigenicity. Proc Natl Acad Sci U S A 89(17), 8165-8169 (1992)
41. I. B. Weinstein: Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 297(5578), 63-64 (2002) (Pubitemid 34743088)
42. M. S. Sheikh, F. Carrier, A. C. Johnson, S. E. Ogdon and A. J. Fornace, Jr.: Identification of an additional p53-responsive site in the human epidermal growth factor receptor gene promotor. Oncogene 15(9), 1095-1101 (1997) (Pubitemid 27401964)
43. C. Kersting, N. Tidow, H. Schmidt, C. Liedtke, J. Neumann, W. Boecker, P. J. van Diest, B. Brandt and H. Buerger: Gene dosage PCR and fluorescence in situ hybridization reveal low frequency of egfr amplifications despite protein overexpression in invasive breast carcinoma. Lab Invest 84(5), 582-587 (2004) (Pubitemid 38858467)
44. J. M. McInerney, M. A. Wilson, K. J. Strand and S. A. Chrysogelos: A strong intronic enhancer element of the EGFR gene is preferentially active in high EGFR expressing breast cancer cells. J Cell Biochem 80(4), 538-549 (2001) (Pubitemid 32127469)
45. T. J. Lynch, D. W. Bell, R. Sordella, S. Gurubhagavatula, R. A. Okimoto, B. W. Brannigan, P. L. Harris, S. M. Haserlat, J. G. Supko, F. G. Haluska, D. N. Louis, D. C. Christiani, J. Settleman and D. A. Haber: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21), 2129-2139 (2004) (Pubitemid 38637993)
46. R. Sordella, D. W. Bell, D. A. Haber and J. Settleman: Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305(5687), 1163-1167 (2004) (Pubitemid 39100331)
47. E. Calvo and J. Baselga: Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. J Clin Oncol 24(14), 2158-2163 (2006) (Pubitemid 46630688)
48. H. Shigematsu, L. Lin, T. Takahashi, M. Nomura, M. Suzuki, Wistuba, II, K. M. Fong, H. Lee, S. Toyooka, N. Shimizu, T. Fujisawa, Z. Feng, J. A. Roth, J. Herz, J. D. Minna and A. F. Gazdar: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97(5), 339-346 (2005) (Pubitemid 40425952)
49. A. G. Pallis, A. Voutsina, A. Kalikaki, J. Souglakos, E. Briasoulis, S. Murray, A. Koutsopoulos, M. Tripaki, E. Stathopoulos, D. Mavroudis and V. Georgoulias: 'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer. Br J Cancer 97(11), 1560-1566 (2007) (Pubitemid 350175853)
50. W. Pao, V. Miller, M. Zakowski, J. Doherty, K. Politi, I. Sarkaria, B. Singh, R. Heelan, V. Rusch, L. Fulton, E. Mardis, D. Kupfer, R. Wilson, M. Kris and H. Varmus: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101(36), 13306-13311 (2004) (Pubitemid 39209661)
51. S. Kobayashi, T. J. Boggon, T. Dayaram, P. A. Janne, O. Kocher, M. Meyerson, B. E. Johnson, M. J. Eck, D. G. Tenen and B. Halmos: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352(8), 786-792 (2005) (Pubitemid 40271173)
52. Y. Yatabe, T. Takahashi and T. Mitsudomi: Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer. Cancer Res 68(7), 2106-2111 (2008) (Pubitemid 351521782)
53. M. Volm, W. Rittgen and P. Drings: Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br J Cancer 77(4), 663-669 (1998) (Pubitemid 28059477)
54. H. Nakamura, N. Kawasaki, M. Taguchi and K. Kabasawa: Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis. Thorax 61(2), 140-145 (2006) (Pubitemid 43235431)
55. A. K. Ganti: Epidermal growth factor receptor signaling in nonsmall cell lung cancer. Cancer Invest 28(5), 515-525 (2010)
56. D. W. Bell, T. J. Lynch, S. M. Haserlat, P. L. Harris, R. A. Okimoto, B. W. Brannigan, D. C. Sgroi, B. Muir, M. J. Riemenschneider, R. B. Iacona, A. D. Krebs, D. H. Johnson, G. Giaccone, R. S. Herbst, C. Manegold, M. Fukuoka, M. G. Kris, J. Baselga, J. S. Ochs and D. A. Haber: Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 23(31), 8081-8092 (2005) (Pubitemid 46657411)
57. M. Maemondo, A. Inoue, K. Kobayashi, S. Sugawara, S. Oizumi, H. Isobe, A. Gemma, M. Harada, H. Yoshizawa, I. Kinoshita, Y. Fujita, S. Okinaga, H. Hirano, K. Yoshimori, T. Harada, T. Ogura, M. Ando, H. Miyazawa, T. Tanaka, Y. Saijo, K. Hagiwara, S. Morita and T. Nukiwa: Gefitinib or chemotherapy for non-smallcell lung cancer with mutated EGFR. N Engl J Med 362(25), 2380-2388 (2010)
58. G. Armengol, F. Rojo, J. Castellvi, C. Iglesias, M. Cuatrecasas, B. Pons, J. Baselga and S. Ramon y Cajal: 4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications. Cancer Res 67(16), 7551-7555 (2007) (Pubitemid 47281345)
59. J. M. McDonald, C. E. Pelloski, A. Ledoux, M. Sun, G. Raso, R. Komaki, Wistuba, II, B. N. Bekele and K. Aldape: Elevated phospho-S6 expression is associated with metastasis in adenocarcinoma of the lung. Clin Cancer Res 14(23), 7832-7837 (2008)
60. O. H. Iwenofu, R. D. Lackman, A. P. Staddon, D. G. Goodwin, H. M. Haupt and J. S. Brooks: Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy. Mod Pathol 21(3), 231-237 (2008) (Pubitemid 351304283)
61. H. Yu and R. Jove: The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 4(2), 97-105 (2004) (Pubitemid 38198738)
62. T. Cortas, R. Eisenberg, P. Fu, J. Kern, L. Patrick and A. Dowlati: Activation state EGFR and STAT-3 as prognostic markers in resected non-small cell lung cancer. Lung Cancer 55(3), 349-355 (2007) (Pubitemid 46343578)
63. H. van Cruijsen, M. G. Ruiz, P. van der Valk, T. D. de Gruijl and G. Giaccone: Tissue micro array analysis of ganglioside N-glycolyl GM3 expression and signal transducer and activator of transcription (STAT)-3 activation in relation to dendritic cell infiltration and microvessel density in non-small cell lung cancer. BMC Cancer 9, 180 (2009)
64. A. Shah, W. A. Swain, D. Richardson, J. Edwards, D. J. Stewart, C. M. Richardson, D. E. Swinson, D. Patel, J. L. Jones and K. J. O'Byrne: Phospho-akt expression is associated with a favorable outcome in non-small cell lung cancer. Clin Cancer Res 11(8), 2930-2936 (2005) (Pubitemid 40525195)
65. J. R. Grandis, S. D. Drenning, Q. Zeng, S. C. Watkins, M. F. Melhem, S. Endo, D. E. Johnson, L. Huang, Y. He and J. D. Kim: Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci U S A 97(8), 4227-4232 (2000) (Pubitemid 30226115)
66. R. Garcia, C. L. Yu, A. Hudnall, R. Catlett, K. L. Nelson, T. Smithgall, D. J. Fujita, S. P. Ethier and R. Jove: Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ 8(12), 1267-1276 (1997) (Pubitemid 28008723)
67. J. Wu, W. W. Wong, F. Khosravi, M. D. Minden and L. Z. Penn: Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatininduced apoptosis. Cancer Res 64(18), 6461-6468 (2004) (Pubitemid 39297901)
68. T. Mukohara, S. Kudoh, S. Yamauchi, T. Kimura, N. Yoshimura, H. Kanazawa, K. Hirata, H. Wanibuchi, S. Fukushima, K. Inoue and J. Yoshikawa: Expression of epidermal growth factor receptor (EGFR) and downstreamactivated peptides in surgically excised non-small-cell lung cancer (NSCLC). Lung Cancer 41(2), 123-130 (2003) (Pubitemid 36842775)
69. J. Brognard, A. S. Clark, Y. Ni and P. A. Dennis: Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61(10), 3986-3997 (2001) (Pubitemid 32720961)
70. C. E. Pelloski, E. Lin, L. Zhang, W. K. Yung, H. Colman, J. L. Liu, S. Y. Woo, A. B. Heimberger, D. Suki, M. Prados, S. Chang, F. G. Barker, 3rd, G. N. Fuller and K. D. Aldape: Prognostic associations of activated mitogenactivated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res 12(13), 3935-3941 (2006) (Pubitemid 44078078)
71. Y. Dobashi, S. Suzuki, H. Matsubara, M. Kimura, S. Endo and A. Ooi: Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas. Cancer 115(1), 107-18 (2009)
72. F. Cappuzzo, E. Magrini, G. L. Ceresoli, S. Bartolini, E. Rossi, V. Ludovini, V. Gregorc, C. Ligorio, A. Cancellieri, S. Damiani, A. Spreafico, C. T. Paties, L. Lombardo, C. Calandri, G. Bellezza, M. Tonato and L. Crino: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 96(15), 1133-1141 (2004) (Pubitemid 39207049)
73. D. A. Altomare and J. R. Testa: Perturbations of the AKT signaling pathway in human cancer. Oncogene 24(50), 7455-7464 (2005) (Pubitemid 41637985)
74. B. R. Balsara, J. Pei, Y. Mitsuuchi, R. Page, A. Klein- Szanto, H. Wang, M. Unger and J. R. Testa: Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis 25(11), 2053-2059 (2004) (Pubitemid 39534841)
75. Y. Dobashi, S. Suzuki, E. Sato, Y. Hamada, T. Yanagawa and A. Ooi: EGFR-dependent and independent activation of Akt/mTOR cascade in bone and soft tissue tumors. Mod Pathol 22(10), 1328-1340 (2009)
76. S. J. Grille, A. Bellacosa, J. Upson, A. J. Klein-Szanto, F. van Roy, W. Lee-Kwon, M. Donowitz, P. N. Tsichlis and L. Larue: The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res 63(9), 2172-2178 (2003) (Pubitemid 36538623)
77. O. David, J. Jett, H. LeBeau, G. Dy, J. Hughes, M. Friedman and A. R. Brody: Phospho-Akt overexpression in non-small cell lung cancer confers significant stageindependent survival disadvantage. Clin Cancer Res 10(20), 6865-6871 (2004) (Pubitemid 39383035)
78. J. Brugarolas, K. Lei, R. L. Hurley, B. D. Manning, J. H. Reiling, E. Hafen, L. A. Witters, L. W. Ellisen and W. G. Kaelin, Jr.: Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev 18(23), 2893-2904 (2004) (Pubitemid 39602308)
79. E. Petroulakis, Y. Mamane, O. Le Bacquer, D. Shahbazian and N. Sonenberg: mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer 94(2), 195-199 (2006) (Pubitemid 43151534)
80. D. C. Fingar, C. J. Richardson, A. R. Tee, L. Cheatham, C. Tsou and J. Blenis: mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mo Cell Biol 24(1), 200-216 (2004) (Pubitemid 38010048)
81. E. Jacinto and M. N. Hall: Tor signalling in bugs, brain and brawn. Nat Rev Mol Cell Biol 4(2), 117-126 (2003) (Pubitemid 36172695)
82. J. Castellvi, A. Garcia, C. Ruiz-Marcellan, J. Hernandez-Losa, V. Peg, M. Salcedo, A. Gil-Moreno and Ya C. SR: Cell signaling in endometrial carcinoma: phosphorylated 4E-binding protein-1 expression in endometrial cancer correlates with aggressive tumors and prognosis. Hum Pathol (2009)
83. J. Castellvi, A. Garcia, F. Rojo, C. Ruiz-Marcellan, A. Gil, J. Baselga and S. Ramon y Cajal: Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer 107(8), 1801-1811 (2006) (Pubitemid 44582949)
84. S. W. Han, T. Y. Kim, P. G. Hwang, S. Jeong, J. Kim, I. S. Choi, D. Y. Oh, J. H. Kim, D. W. Kim, D. H. Chung, S. A. Im, Y. T. Kim, J. S. Lee, D. S. Heo, Y. J. Bang and N. K. Kim: Predictive and prognostic impact of epidermal growth factor receptor mutation in non-smallcell lung cancer patients treated with gefitinib. J Clin Oncol 23(11), 2493-2501 (2005) (Pubitemid 47050839)
85. C. Gridelli, P. Maione and A. Rossi: The potential role of mTOR inhibitors in non-small cell lung cancer. Oncologist 13(2), 139-147 (2008) (Pubitemid 351342577)
86. S. K. Pal, R. A. Figlin and K. L. Reckamp: The role of targeting mammalian target of rapamycin in lung cancer. Clin Lung Cancer 9(6), 340-345 (2008)
87. G. Otulakowski, W. Duan and H. O'Brodovich: Global and Gene-specific Translational Regulation in Rat Lung Development. Am J Respir Cell Mol Biol (2008)
88. L. Xiao, Y. C. Wang, W. S. Li and Y. Du: The role of mTOR and phospho-p70S6K in pathogenesis and progression of gastric carcinomas: an immunohistochemical study on tissue microarray. J Exp Clin Cancer Res 28, 152 (2009)
89. X. F. Zhao and R. B. Gartenhaus: Phospho-p70S6K and cdc2/cdk1 as therapeutic targets for diffuse large B-cell lymphoma. Expert Opin Ther Targets 13(9), 1085-1093 (2009)
90. L. Cen, K. J. Arnoczky, F. C. Hsieh, H. J. Lin, S. J. Qualman, S. Yu, H. Xiang and J. Lin: Phosphorylation profiles of protein kinases in alveolar and embryonal rhabdomyosarcoma. Mod Pathol 20(9), 936-946 (2007) (Pubitemid 47267820)
91. E. Conde, B. Angulo, M. Tang, M. Morente, J. Torres- Lanzas, A. Lopez-Encuentra, F. Lopez-Rios and M. Sanchez-Cespedes: Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling. Clin Cancer Res 12(3 Pt 1), 710-717 (2006) (Pubitemid 43259849)
92. C. Wu, M. Wangpaichitr, L. Feun, M. T. Kuo, C. Robles, T. Lampidis and N. Savaraj: Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. Mol Cancer 4(1), 25 (2005)
93. J. Zhang, P. L. Yang and N. S. Gray: Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 9(1), 28-39 (2009)
94. E. Van Cutsem, C. H. Kohne, E. Hitre, J. Zaluski, C. R. Chang Chien, A. Makhson, G. D'Haens, T. Pinter, R. Lim, G. Bodoky, J. K. Roh, G. Folprecht, P. Ruff, C. Stroh, S. Tejpar, M. Schlichting, J. Nippgen and P. Rougier: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360(14), 1408-1417 (2009)
95. E. Aboud-Pirak, E. Hurwitz, M. E. Pirak, F. Bellot, J. Schlessinger and M. Sela: Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J Natl Cancer Inst 80(20), 1605-1611 (1988) (Pubitemid 19006809)
96. F. Ciardiello and G. Tortora: A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 7(10), 2958-2970 (2001) (Pubitemid 32963812)
97. J. Brognard and P. A. Dennis: Variable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small molecules or dominant negative mutants. Cell Death Differ 9(9), 893-904 (2002) (Pubitemid 35023605)
98. H. L. Gomez, D. C. Doval, M. A. Chavez, P. C. Ang, Z. Aziz, S. Nag, C. Ng, S. X. Franco, L. W. Chow, M. C. Arbushites, M. A. Casey, M. S. Berger, S. H. Stein and G. W. Sledge: Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 26(18), 2999-3005 (2008)
99. C. E. Geyer, J. Forster, D. Lindquist, S. Chan, C. G. Romieu, T. Pienkowski, A. Jagiello-Gruszfeld, J. Crown, A. Chan, B. Kaufman, D. Skarlos, M. Campone, N. Davidson, M. Berger, C. Oliva, S. D. Rubin, S. Stein and D. Cameron: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355(26), 2733-2743 (2006) (Pubitemid 46021510)
100. J. P. Eder, G. I. Shapiro, L. J. Appleman, A. X. Zhu, D. Miles, H. Keer, B. Cancilla, F. Chu, S. Hitchcock-Bryan, L. Sherman, S. McCallum, E. I. Heath, S. A. Boerner and P. M. LoRusso: A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res 16(13), 3507-3516 (2010)
101. A. H. Evans, S. Pancholi, I. Farmer, A. Thornhill, D. B. Evans, S. R. Johnston, M. Dowsett and L. A. Martin: EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy. Br J Cancer 102(8), 1235-1243 (2010)
102. F. A. Schutz, T. K. Choueiri and C. N. Sternberg: Pazopanib: Clinical development of a potent anti-angiogenic drug. Crit Rev Oncol Hematol (2010)
103. T. Shimamura, H. Ji, Y. Minami, R. K. Thomas, A. M. Lowell, K. Shah, H. Greulich, K. A. Glatt, M. Meyerson, G. I. Shapiro and K. K. Wong: Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV-G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. Cancer Res 66(13), 6487-6491 (2006) (Pubitemid 44085601)
104. P. A. Janne, J. von Pawel, R. B. Cohen, L. Crino, C. A. Butts, S. S. Olson, I. A. Eiseman, A. A. Chiappori, B. Y. Yeap, P. F. Lenehan, K. Dasse, M. Sheeran and P. D. Bonomi: Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer. J Clin Oncol 25(25), 3936-3944 (2007) (Pubitemid 47477271)
105. N. Minkovsky and A. Berezov: BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors. Curr Opin Investig Drugs 9(12), 1336-1346 (2008)
106. J. Bean, C. Brennan, J. Y. Shih, G. Riely, A. Viale, L. Wang, D. Chitale, N. Motoi, J. Szoke, S. Broderick, M. Balak, W. C. Chang, C. J. Yu, A. Gazdar, H. Pass, V. Rusch, W. Gerald, S. F. Huang, P. C. Yang, V. Miller, M. Ladanyi, C. H. Yang and W. Pao: MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 104(52), 20932-20937 (2007)
107. J. A. Engelman, K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland, J. O. Park, N. Lindeman, C. M. Gale, X. Zhao, J. Christensen, T. Kosaka, A. J. Holmes, A. M. Rogers, F. Cappuzzo, T. Mok, C. Lee, B. E. Johnson, L. C. Cantley and P. A. Janne: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316(5827), 1039-1043 (2007) (Pubitemid 46799492)
108. H. Y. Zou, Q. Li, J. H. Lee, M. E. Arango, S. R. McDonnell, S. Yamazaki, T. B. Koudriakova, G. Alton, J. J. Cui, P. P. Kung, M. D. Nambu, G. Los, S. L. Bender, B. Mroczkowski and J. G. Christensen: An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 67(9), 4408-4417 (2007) (Pubitemid 46815090)
109. L. Toral-Barza, W. G. Zhang, X. Huang, L. A. McDonald, E. J. Salaski, L. R. Barbieri, W. D. Ding, G. Krishnamurthy, Y. B. Hu, J. Lucas, V. S. Bernan, P. Cai, J. I. Levin, T. S. Mansour, J. J. Gibbons, R. T. Abraham and K. Yu: Discovery of lactoquinomycin and related pyranonaphthoquinones as potent and allosteric inhibitors of AKT/PKB: mechanistic involvement of AKT catalytic activation loop cysteines. Mol Cancer Ther 6(11), 3028-3038 (2007) (Pubitemid 350206781)
110. V. Papa, P. L. Tazzari, F. Chiarini, A. Cappellini, F. Ricci, A. M. Billi, C. Evangelisti, E. Ottaviani, G. Martinelli, N. Testoni, J. A. McCubrey and A. M. Martelli: Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells. Leukemia 22(1), 147-160 (2008)
111. M. Mandal, S. Kim, M. N. Younes, S. A. Jasser, A. K. El-Naggar, G. B. Mills and J. N. Myers: The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells. Br J Cancer 92(10), 1899-1905 (2005) (Pubitemid 40826139)
112. M. A. Blaskovich, J. Sun, A. Cantor, J. Turkson, R. Jove and S. M. Sebti: Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 63(6), 1270-1279 (2003) (Pubitemid 36348705)
113. P. Lanuti, V. Bertagnolo, L. Pierdomenico, A. Bascelli, E. Santavenere, L. Alinari, S. Capitani, S. Miscia and M. Marchisio: Enhancement of TRAIL cytotoxicity by AG-490 in human ALL cells is characterized by downregulation of cIAP-1 and cIAP-2 through inhibition of Jak2/Stat3. Cell Res 19(9), 1079-1089 (2009)
114. J. Amann, S. Kalyankrishna, P. P. Massion, J. E. Ohm, L. Girard, H. Shigematsu, M. Peyton, D. Juroske, Y. Huang, J. Stuart Salmon, Y. H. Kim, J. R. Pollack, K. Yanagisawa, A. Gazdar, J. D. Minna, J. M. Kurie and D. P. Carbone: Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 65(1), 226-235 (2005) (Pubitemid 40070814)
115. S. E. Wang, A. Narasanna, M. Perez-Torres, B. Xiang, F. Y. Wu, S. Yang, G. Carpenter, A. F. Gazdar, S. K. Muthuswamy and C. L. Arteaga: HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 10(1), 25-38 (2006)
116. W. Pao, T. Y. Wang, G. J. Riely, V. A. Miller, Q. Pan, M. Ladanyi, M. F. Zakowski, R. T. Heelan, M. G. Kris and H. E. Varmus: KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2(1), e17 (2005)
117. I. Sansal and W. R. Sellers: The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 22(14), 2954-2963 (2004) (Pubitemid 41079915)
118. L. Z. Liu, X. D. Zhou, G. Qian, X. Shi, J. Fang and B. H. Jiang: AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. Cancer Res 67(13), 6325-6332 (2007) (Pubitemid 47037515)
119. E. K. Rowinsky: Targeting the molecular target of rapamycin (mTOR). Curr Opin Oncol 16(6), 564-575 (2004) (Pubitemid 39482975)
120. Y. Mamane, E. Petroulakis, O. LeBacquer and N. Sonenberg: mTOR, translation initiation and cancer. Oncogene 25(48), 6416-6422 (2006) (Pubitemid 44582285)
121. D. M. Sabatini: mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 6(9), 729-734 (2006) (Pubitemid 44286004)
122. S. La Monica, M. Galetti, R. R. Alfieri, A. Cavazzoni, A. Ardizzoni, M. Tiseo, M. Capelletti, M. Goldoni, S. Tagliaferri, A. Mutti, C. Fumarola, M. Bonelli, D. Generali and P. G. Petronini: Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines. Biochem Pharmacol 78(5), 460-468 (2009)
123. I. Beuvink, A. Boulay, S. Fumagalli, F. Zilbermann, S. Ruetz, T. O'Reilly, F. Natt, J. Hall, H. A. Lane and G. Thomas: The mTOR inhibitor RAD001 sensitizes tumor cells to DNAdamaged induced apoptosis through inhibition of p21 translation. Cell 120(6), 747-759 (2005) (Pubitemid 40568794)
124. S. Wullschleger, R. Loewith and M. N. Hall: TOR signaling in growth and metabolism. Cell 124(3), 471-484 (2006) (Pubitemid 43199434)
125. M. A. Bjornsti and P. J. Houghton: Lost in translation: dysregulation of cap-dependent translation and cancer. Cancer Cell 5(6), 519-23 (2004) (Pubitemid 38748913)
126. A. J. Pantuck, D. B. Seligson, T. Klatte, H. Yu, J. T. Leppert, L. Moore, T. O'Toole, J. Gibbons, A. S. Belldegrun and R. A. Figlin: Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 109(11), 2257-2267 (2007) (Pubitemid 46801555)
127. A. R. Tee and C. G. Proud: DNA-damaging agents cause inactivation of translational regulators linked to mTOR signalling. Oncogene 19(26), 3021-3031 (2000) (Pubitemid 30389093)
128. K. E. O'Reilly, F. Rojo, Q. B. She, D. Solit, G. B. Mills, D. Smith, H. Lane, F. Hofmann, D. J. Hicklin, D. L. Ludwig, J. Baselga and N. Rosen: mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66(3), 1500-1508 (2006) (Pubitemid 43259931)
129. L. Fu, Y. A. Kim, X. Wang, X. Wu, P. Yue, S. Lonial, F. R. Khuri and S. Y. Sun: Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy. Cancer Res 69(23), 8967-8976 (2009)
130. Q. W. Fan, Z. A. Knight, D. D. Goldenberg, W. Yu, K. E. Mostov, D. Stokoe, K. M. Shokat and W. A. Weiss: A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9(5), 341-349 (2006) (Pubitemid 43668732)
131. F. Morgillo, J. K. Woo, E. S. Kim, W. K. Hong and H. Y. Lee: Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res 66(20), 10100-10111 (2006) (Pubitemid 44672064)
132. A. B. Motoyama, N. E. Hynes and H. A. Lane: The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factorrelated peptides. Cancer Res 62(11), 3151-3158 (2002) (Pubitemid 34602408)
133. R. Bianco, I. Shin, C. A. Ritter, F. M. Yakes, A. Basso, N. Rosen, J. Tsurutani, P. A. Dennis, G. B. Mills and C. L. Arteaga: Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 22(18), 2812-2822 (2003) (Pubitemid 36609595)
134. E. Buck, A. Eyzaguirre, E. Brown, F. Petti, S. McCormack, J. D. Haley, K. K. Iwata, N. W. Gibson and G. Griffin: Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther 5(11), 2676-2684 (2006) (Pubitemid 44848994)
135. C. Gridelli, P. Maione, M. L. Ferrara and A. Rossi: Cetuximab and other anti-epidermal growth factor receptor monoclonal antibodies in the treatment of non-small cell lung cancer. Oncologist 14(6), 601-611 (2009)